🚨 $MRNA SELL-OFF AFTER PHASE 3 DATA RELEASE ⚡
Entry: 202.63 ⚡
Stop Loss: 180.80 ⚠️
The Phase 3 INTerpath‑001 read‑out sparked a sharp 17.5% sell‑off, carving the price down to $180.80 – a classic liquidity sweep after a 177% rally in August. 📊 Smart money appears to be cashing in on the over‑extension, resetting the order block around $202.63.
Meanwhile, AI‑driven biotech partnerships from OpenAI to Nvidia are expanding the fundamental narrative, but the market is pricing the near‑term risk, not the long‑term upside. 🌊 Expect the next demand zone to hold if volume steadies, and watch for a retest of the $202.63 level as buyers re‑enter. 💬 Will the liquidity hunt conclude here or set the stage for a deeper pullback? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #MRNA #SellTheNews #Biotech #AI #Crypto
🔥 💎
Entry: 202.63 ⚡
Stop Loss: 180.80 ⚠️
The Phase 3 INTerpath‑001 read‑out sparked a sharp 17.5% sell‑off, carving the price down to $180.80 – a classic liquidity sweep after a 177% rally in August. 📊 Smart money appears to be cashing in on the over‑extension, resetting the order block around $202.63.
Meanwhile, AI‑driven biotech partnerships from OpenAI to Nvidia are expanding the fundamental narrative, but the market is pricing the near‑term risk, not the long‑term upside. 🌊 Expect the next demand zone to hold if volume steadies, and watch for a retest of the $202.63 level as buyers re‑enter. 💬 Will the liquidity hunt conclude here or set the stage for a deeper pullback? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #MRNA #SellTheNews #Biotech #AI #Crypto
🔥 💎